Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Shockwave therapy effective for erectile dysfunction

17 Mar 2018
Sexual health in men – supplements vs medication

The total number of shockwave therapy significantly affects treatment efficacy, according to a recent study, which has shown improved sexual function in erectile dysfunction patients undergoing 12 vs 6 shockwave therapy sessions.

The researchers randomized 42 adults with vasculogenic erectile dysfunction to receive low-intensity shockwave therapy either once (group A; n=21) or twice (group B; n=21) a week for 6 consecutive weeks. Six additional sessions were offered for the second phase of the study, where group A received two sessions per week and group B received one session per week.

In the entire cohort the mean score in the erectile function domain of the International Index for Erectile Function (IIEF-EF) significantly increased after the 6-week treatment (15.8±3.7 to 19.9±3.8; p<0.001).

For group A, scores after 1 month, 3 months and 6 months were 19.5, 19.0 and 19.3 points, respectively, indicating significant improvements from the 16.2 score at baseline (p<0.001). The respective improvements in group B were greater (20.6, 20.6 and 20.5 points; p<0.001).

At 6 months, group B had significantly better outcomes in the Sexual Encounter Profile than group A. Compared to 47 percent in group A, 65 percent in group B affirmed that their erections lasted long enough for successful intercourse. The between-group difference reached significance (p=0.02).

Retreatment with the six additional sessions resulted in further significant improvements in IIEF-EF scores. Scores increased from 20.3±3.5 points at baseline to 22.1±4.3 points at the 6-month follow-up after the six additional sessions (p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.